BR112014005596A2 - método para aumentar a apresentação de antígeno cs6 de etec na superfície da célula, método para a fabricação de uma vacina de célula inteira morta, célula, e, vacina para a imunização contra etec que expressa cs6 - Google Patents

método para aumentar a apresentação de antígeno cs6 de etec na superfície da célula, método para a fabricação de uma vacina de célula inteira morta, célula, e, vacina para a imunização contra etec que expressa cs6

Info

Publication number
BR112014005596A2
BR112014005596A2 BR112014005596A BR112014005596A BR112014005596A2 BR 112014005596 A2 BR112014005596 A2 BR 112014005596A2 BR 112014005596 A BR112014005596 A BR 112014005596A BR 112014005596 A BR112014005596 A BR 112014005596A BR 112014005596 A2 BR112014005596 A2 BR 112014005596A2
Authority
BR
Brazil
Prior art keywords
cell
etec
vaccine
increasing
manufacturing
Prior art date
Application number
BR112014005596A
Other languages
English (en)
Other versions
BR112014005596B1 (pt
Inventor
Svennerholm Ann-Mari
Tobias Joshua
Carlin Nils
Original Assignee
Scandinavian Biopharma Holding Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scandinavian Biopharma Holding Ab filed Critical Scandinavian Biopharma Holding Ab
Publication of BR112014005596A2 publication Critical patent/BR112014005596A2/pt
Publication of BR112014005596B1 publication Critical patent/BR112014005596B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0258Escherichia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245Escherichia (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • G01N33/56916Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
BR112014005596-3A 2011-09-12 2012-09-10 Método para aumentar a apresentação de antígeno cs6 de etec na superfície da célula, método para a fabricação de uma vacina de célula inteira morta, e, vacina para a imunização contra etec que expressa cs6 BR112014005596B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161533405P 2011-09-12 2011-09-12
US61/533,405 2011-09-12
SE1150821 2011-09-12
SE1150821-5 2011-09-12
PCT/EP2012/067598 WO2013037718A1 (en) 2011-09-12 2012-09-10 Method for increasing etec cs6 antigen presentation on cell surface and products obtainable thereof

Publications (2)

Publication Number Publication Date
BR112014005596A2 true BR112014005596A2 (pt) 2017-04-04
BR112014005596B1 BR112014005596B1 (pt) 2020-03-24

Family

ID=47882650

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014005596-3A BR112014005596B1 (pt) 2011-09-12 2012-09-10 Método para aumentar a apresentação de antígeno cs6 de etec na superfície da célula, método para a fabricação de uma vacina de célula inteira morta, e, vacina para a imunização contra etec que expressa cs6

Country Status (15)

Country Link
US (6) US9273103B2 (pt)
EP (1) EP2750701B1 (pt)
JP (1) JP5985643B2 (pt)
KR (1) KR101940357B1 (pt)
CN (1) CN103917244B (pt)
AU (1) AU2012307540B2 (pt)
BR (1) BR112014005596B1 (pt)
CA (1) CA2846279C (pt)
DK (1) DK2750701T3 (pt)
ES (1) ES2558454T3 (pt)
HK (1) HK1199210A1 (pt)
PL (1) PL2750701T3 (pt)
PT (1) PT2750701E (pt)
RU (1) RU2628698C2 (pt)
WO (1) WO2013037718A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273103B2 (en) * 2011-09-12 2016-03-01 Scandinavian Biopharma Holding Ab Method for increasing ETEC CS6 antigen presentation on cell surface and products obtainable thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9100556D0 (sv) * 1991-02-26 1991-02-26 Holmgren Jan Preparation and use of formalin-killed colonization-factor-antigen (cfa)-expressing e coli organisms for vaccination against enteric infection/diarrhea caused by enterotoxigenic e coli bacteria in humans
CA2233935A1 (en) * 1995-10-05 1997-04-10 Immucell Corporation Process for isolating immunoglobulins in whey
US20020034522A1 (en) * 1998-03-13 2002-03-21 Flynn, Thiel, Boutell, And Tanis, P.C. Use of a strain of pasteurella haemolytica of a particular serotype for preparing a vaccine against bovine pasteurellosis due to pasteurella haemolytica
SE515285C2 (sv) * 1998-12-18 2001-07-09 Sbl Vaccin Ab Oralt vaccin mot diarré
PT1372708E (pt) * 2001-02-13 2008-09-29 Us Gov Sec Army Vacina para imunização transcutânea
GB0121998D0 (en) * 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
US7217541B2 (en) * 2002-02-25 2007-05-15 United States Of America As Represented By The Secretary Of The Army Method of making CS6 antigen vaccine for treating, preventing, or inhibiting enterotoxigenic Escherichia coli infections
RU2242993C2 (ru) * 2002-11-18 2004-12-27 Федеральное государственное унитарное предприятие Пермское научно-производственное объединение "Биомед" Способ приготовления вакцины для профилактики хламидийных инфекций у человека
CN101378780A (zh) * 2006-02-01 2009-03-04 Sbl疫苗公司 重组细菌中的肠产毒性大肠杆菌定居因子(cf)抗原
WO2013037397A1 (en) * 2011-09-12 2013-03-21 Scandinavian Biopharma Holding Ab Vaccine for protection against etec induced diarrhea comprising dmlt.
US9273103B2 (en) * 2011-09-12 2016-03-01 Scandinavian Biopharma Holding Ab Method for increasing ETEC CS6 antigen presentation on cell surface and products obtainable thereof

Also Published As

Publication number Publication date
BR112014005596B1 (pt) 2020-03-24
CN103917244A (zh) 2014-07-09
US9790257B2 (en) 2017-10-17
US20240140996A1 (en) 2024-05-02
US9273103B2 (en) 2016-03-01
JP2014531428A (ja) 2014-11-27
AU2012307540A1 (en) 2014-02-27
HK1199210A1 (zh) 2015-06-26
RU2628698C2 (ru) 2017-08-21
US10851140B2 (en) 2020-12-01
CA2846279C (en) 2021-05-18
DK2750701T3 (en) 2016-01-11
WO2013037718A1 (en) 2013-03-21
US20180079787A1 (en) 2018-03-22
US20210147491A1 (en) 2021-05-20
RU2014114284A (ru) 2015-10-20
KR20140068187A (ko) 2014-06-05
PT2750701E (pt) 2016-02-01
ES2558454T3 (es) 2016-02-04
US20160251401A1 (en) 2016-09-01
CN103917244B (zh) 2016-07-06
AU2012307540B2 (en) 2016-09-22
KR101940357B1 (ko) 2019-01-18
CA2846279A1 (en) 2013-03-21
US20140178436A1 (en) 2014-06-26
PL2750701T3 (pl) 2016-03-31
US20190389913A1 (en) 2019-12-26
EP2750701A1 (en) 2014-07-09
US11820798B2 (en) 2023-11-21
US10414806B2 (en) 2019-09-17
JP5985643B2 (ja) 2016-09-06
EP2750701B1 (en) 2015-10-21

Similar Documents

Publication Publication Date Title
BR112015000530A2 (pt) vacina de antígeno micobacteriano.
BR112015002981A2 (pt) vacina estável em meio líquido, e, métodos para vacinação de um canino, e para fabricar a vacina estável em meio líquido
EP2970907A4 (en) Nanoscale artificial antigen presenting cells
ZA201308461B (en) Multiple antigen presenting immunogenic composition and methods and uses thereof
CL2012003299A1 (es) Vacuna que comprende uno o mas antigenos, uno o mas oligonucleotidos inmunoestimuladores aislados y colesterol; metodo para inducir una respuesta inmune antigeno específica en un sujeto que necesita de la misma.
BR112014002174A2 (pt) estrutura de válvula cardíaca, estrutura de válvula cardíaca em múltiplas-lâminas e método para fabricar uma estrutura de válvula cardíaca
BR112012019757A2 (pt) composição imunogênica, e, método para induzir uma resposta imune a um polissacarídeo capsular
BR112013030449A2 (pt) unidade de acondicionamento sem película e método para produzir uma unidade de acondicionamento.
CL2013003031A1 (es) Metodo para estratificacion a base de bcma en pacientes con mieloma multiple; anticuerpo anti-bcma.
BR112012022433A2 (pt) Método para fabricação de um transdutor de dobra, uma microbomba e uma microválvula, microbomba e microválvula
BR112014008603A2 (pt) tablete, e, método para produzir um tablete
BR112015012601A2 (pt) método e aparelho para fabricar uma peça pela fusão de pó com o auxílio de um feixe de alta energia
BR112014010433A2 (pt) método e máquina para produzir uma cápsula de uso único para bebidas e cápsula obtida com o método
BR112013033803A2 (pt) formulação integrada com microagulha, e, método para administrar uma substância
BR112013029498A2 (pt) “método para produzir um suíno geneticamente modificado.”
BR112013020875A2 (pt) método para indução de uma resposta imune específica para um imunógeno em um indivíduo.
BR112014006568A2 (pt) métodos para produzir uma película lipídica e lipossomas, película lipídica ou lipossoma, lipossoma, e, composição imunológica
CL2014001960A1 (es) Metodo para producir una composición que contiene galacto-oligosacáridos.
BR112014019575A8 (pt) método para a produção de uma solução de açucar, solução de açucar e método para a produção do etanol
BR112013025716A2 (pt) cepa bacteriana recombinante, processo para a produção de uma cepa de zymomonas e método para a produção de etanol
BR112014014285A2 (pt) composição, e, método para fabricar uma composição
BR112015028733A2 (pt) membrana, e método para fabricar uma membrana.
BR112013030538A2 (pt) conjunto de pistão e método para formar o mesmo.
BR112014000217A2 (pt) formulação e método para a criação de uma formulação que estabiliza a proteína terapêutica
BR112014015527A8 (pt) cepa de lactobacillus mucosae, método para a obtenção de uma cepa e de uma fração de célula, composição e método para a obtenção de uma composição

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/09/2012, OBSERVADAS AS CONDICOES LEGAIS.